KR950010893A - 자궁내막증 억제 방법 - Google Patents

자궁내막증 억제 방법 Download PDF

Info

Publication number
KR950010893A
KR950010893A KR1019940026164A KR19940026164A KR950010893A KR 950010893 A KR950010893 A KR 950010893A KR 1019940026164 A KR1019940026164 A KR 1019940026164A KR 19940026164 A KR19940026164 A KR 19940026164A KR 950010893 A KR950010893 A KR 950010893A
Authority
KR
South Korea
Prior art keywords
compound
chem
formula
endometriosis
piperidino
Prior art date
Application number
KR1019940026164A
Other languages
English (en)
Inventor
존 블랙 래리
조셉 컬리난 죠오지
윌리엄 드래퍼 마이클
데이비드 존스 찰스
에드워드 세일러 데이비드
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950010893A publication Critical patent/KR950010893A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cable Transmission Systems, Equalization Of Radio And Reduction Of Echo (AREA)

Abstract

본 발명은 자궁내막증의 치료를 필요로 하는 인간에게 하기 일반식(I)의 화합물, 또는 그의 약학적으로 허용 가능한 염 또는 용매화물의 유효량을 투여함을 포함하는, 자궁내막증을 억제하는 방법에 관한 것이다 :
상기식에서, R1및 R3은 독립적으로 수소, -CH3,
(여기서, Ar은 선택적으로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 구성되는 그룹으로부터 선택된다.

Description

자궁내막증 억제 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 자궁내막증을 억제하는데 유용한 하기 일반식(I)와 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서, R1및 R3은 독립적으로 수소, -CH3,
    (여기서, Ar은 선택적으로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 구성되는 그룹으로부터 선택된다.
  2. 제1항에 있어서. 상기 화합물이 하이드로클로라이드 염인 화합물.
  3. 제1항에 있어서, 예방적으로 투여하는 화합물.
  4. 제1항에 있어서, 상기 화합물이 하기 구조식 또는 그의 하이드로클로라이드 염인 화합물:
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940026164A 1993-10-15 1994-10-13 자궁내막증 억제 방법 KR950010893A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8/138,643 1993-10-15
US08/138,643 US5461065A (en) 1993-10-15 1993-10-15 Methods for inhibiting endometriosis

Publications (1)

Publication Number Publication Date
KR950010893A true KR950010893A (ko) 1995-05-15

Family

ID=22482966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940026164A KR950010893A (ko) 1993-10-15 1994-10-13 자궁내막증 억제 방법

Country Status (25)

Country Link
US (2) US5461065A (ko)
EP (1) EP0652005B1 (ko)
JP (1) JPH07188014A (ko)
KR (1) KR950010893A (ko)
CN (1) CN1049335C (ko)
AT (1) ATE203404T1 (ko)
AU (1) AU677700B2 (ko)
CA (1) CA2118092A1 (ko)
CZ (1) CZ287246B6 (ko)
DE (1) DE69427800T2 (ko)
DK (1) DK0652005T3 (ko)
ES (1) ES2157957T3 (ko)
GR (1) GR3036971T3 (ko)
HU (1) HUT71235A (ko)
IL (1) IL111284A (ko)
NO (1) NO311242B1 (ko)
NZ (1) NZ264677A (ko)
PH (1) PH31261A (ko)
PT (1) PT652005E (ko)
RU (1) RU2157203C2 (ko)
SG (1) SG43319A1 (ko)
SI (1) SI0652005T1 (ko)
TW (1) TW296382B (ko)
UA (1) UA26930C2 (ko)
ZA (1) ZA948029B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (ja) 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
IL115018A0 (en) * 1994-08-22 1995-12-08 Lilly Co Eli Methods of inhibiting primary endometrial hyperplasia
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses
US5554600A (en) * 1995-01-20 1996-09-10 Eli Lilly And Company Methods for inhibiting endometriosis
EP0747380B1 (en) * 1995-06-07 1998-09-30 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
KR970002795A (ko) 1995-10-30 1997-01-28 모리 하루오 네비게이션(navigation)장치
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US5942539A (en) * 1997-10-03 1999-08-24 Wake Forest University Methods of treating or preventing endometriosis with phytoestrogens
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
KR20010080254A (ko) * 1998-11-26 2001-08-22 야마구찌 다까시 주기 투여용 의약조성물
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
WO2002056903A2 (en) * 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
EP1395563B1 (en) * 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
DK1401446T3 (da) * 2001-05-22 2005-05-23 Lilly Co Eli Tetrahydroquinolinderivater til inhiberingen af sygdomme forbundet med estrogenmangel eller med en urelgelmæssig fysiologisk reaktion til endogent estrogen
JP2005535623A (ja) * 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療における、チオ−オキシインドール誘導体の使用
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
SG186333A1 (en) 2010-06-16 2013-01-30 Endorech Inc Methods of treating or preventing estrogen-related diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
SE500453C2 (sv) * 1991-10-07 1994-06-27 Karobio Ab Ett in vitro förfarande för utvärdering av en substans effekter
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
IL111284A (en) 2000-02-29
NO943879L (no) 1995-04-18
RU2157203C2 (ru) 2000-10-10
US5693656A (en) 1997-12-02
AU7578794A (en) 1995-05-04
ZA948029B (en) 1996-04-15
CA2118092A1 (en) 1995-04-16
US5461065A (en) 1995-10-24
JPH07188014A (ja) 1995-07-25
CN1107043A (zh) 1995-08-23
UA26930C2 (uk) 1999-12-29
CZ287246B6 (en) 2000-10-11
PT652005E (pt) 2001-11-30
CN1049335C (zh) 2000-02-16
HUT71235A (en) 1995-11-28
EP0652005B1 (en) 2001-07-25
CZ253794A3 (en) 1995-05-17
IL111284A0 (en) 1994-12-29
NO943879D0 (no) 1994-10-13
DE69427800D1 (de) 2001-08-30
TW296382B (ko) 1997-01-21
RU94036772A (ru) 1996-08-27
DE69427800T2 (de) 2001-12-06
SG43319A1 (en) 1997-10-17
EP0652005A1 (en) 1995-05-10
ES2157957T3 (es) 2001-09-01
AU677700B2 (en) 1997-05-01
DK0652005T3 (da) 2001-09-24
PH31261A (en) 1998-06-18
GR3036971T3 (en) 2002-01-31
HU9402959D0 (en) 1995-02-28
ATE203404T1 (de) 2001-08-15
NO311242B1 (no) 2001-11-05
SI0652005T1 (en) 2001-12-31
NZ264677A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
KR950010893A (ko) 자궁내막증 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
KR950010890A (ko) 폐경기 증후군의 치료방법
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016733A (ko) 난소 발육부전, 사춘기 지연, 또는 성적 유치증의 억제방법
KR950016735A (ko) 터너 증후군의 억제 방법
KR950016729A (ko) 유방 질환의 억제 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR970705384A (ko) 골 보철 파손의 억제 방법(methods for inhibiting bone prosthesis degeneration)
KR950016741A (ko) 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법
KR950016728A (ko) 여성에서 다모증 및 탈모증을 억제하는 방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application